We have recently demonstrated that histone deacetylase inhibitor, Vorinostat, applied as a single therapy or in combination with caspase-8 downregulation exhibits high anti-tumoral activity on endometrial carcinoma cell lines. In the present study, we have assessed the signalling processes underlying anti-tumoral effects of Vorinostat. Increasing evidence suggests that reactive oxygen species are responsible for histone deacetylase inhibitor-induced cell killing. We have found that Vorinostat induces formation of reactive oxygen species and DNA damage. To investigate the role of oxidative stress as anti-neoplastic mechanism, we have evaluated the effects of different antioxidants (Bha, Nac and Tiron) on endometrial carcinoma cell line Ishikawa treated with Vorinostat. We show that Bha, Nac and Tiron markedly inhibited the cytotoxic effects of Vorinostat, increasing cell viability in vitro. We found that all three antioxidants did not inhibited accumulation of acetyl Histone H4, so that antioxidants did not inhibit Vorinostat activity. Finally, we have evaluated the effects of antioxidants on anti-tumoral activity of Vorinostat as monotherapy or in combination with caspase-8 downregulation in vivo. Interestingly, antioxidants blocked the reduction of tumour growth caused by Vorinostat, but they were unable to inhibit anti-tumoral activity of Vorinostat plus caspase-8 inhibition.
References
[1]
Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, et al. (2001) Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1: 194–202. doi: 10.1038/35106079
[2]
Barneda-Zahonero B, Parra M (2012) Histone deacetylases and cancer. Mol Oncol 6: 579–589. doi: 10.1016/j.molonc.2012.07.003
[3]
Ropero S, Esteller M (2007) The role of histone deacetylases (HDACs) in human cancer. Mol Oncol 1: 19–25. doi: 10.1016/j.molonc.2007.01.001
[4]
Guasconi V, Ait-Si-Ali S (2004) Chromatin dynamics and cancer. Cancer Biol Ther 3: 825–830. doi: 10.4161/cbt.3.9.1102
[5]
Gilbert J, Gore SD, Herman JG, Carducci MA (2004) The clinical application of targeting cancer through histone acetylation and hypomethylation. Clin Cancer Res 10: 4589–4596. doi: 10.1158/1078-0432.ccr-03-0297
[6]
He H, Lehming N (2003) Global effects of histone modifications. Brief Funct Genomic Proteomic 2: 234–243.
[7]
Legube G, Trouche D (2003) Regulating histone acetyltransferases and deacetylases. EMBO Rep 4: 944–947. doi: 10.1038/sj.embor.embor941
[8]
Singh BN, Zhang G, Hwa YL, Li J, Dowdy SC, et al. (2010) Nonhistone protein acetylation as cancer therapy targets. Expert Rev Anticancer Ther 10: 935–954. doi: 10.1586/era.10.62
[9]
Bi G, Jiang G (2006) The molecular mechanism of HDAC inhibitors in anticancer effects. Cell Mol Immunol 3: 285–290.
[10]
Villar-Garea A, Esteller M (2004) Histone deacetylase inhibitors: understanding a new wave of anticancer agents. Int J Cancer 112: 171–178. doi: 10.1002/ijc.20372
[11]
La Thangue NB (2004) Histone deacetylase inhibitors and cancer therapy. J Chemother 16 Suppl 464–67. doi: 10.1179/joc.2004.16.supplement-1.64
[12]
Mei S, Ho AD, Mahlknecht U (2004) Role of histone deacetylase inhibitors in the treatment of cancer (Review). Int J Oncol 25: 1509–1519. doi: 10.3892/ijo.25.6.1509
[13]
Catalano MG, Fortunati N, Pugliese M, Marano F, Ortoleva L, et al. (2012) Histone deacetylase inhibition modulates E-cadherin expression and suppresses migration and invasion of anaplastic thyroid cancer cells. J Clin Endocrinol Metab 97: E1150–1159. doi: 10.1210/jc.2011-2970
[14]
Catalano MG, Pugliese M, Gargantini E, Grange C, Bussolati B, et al. (2012) Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo. Int J Cancer 130: 694–704. doi: 10.1002/ijc.26057
[15]
Kubo M, Kanaya N, Petrossian K, Ye J, Warden C, et al. (2013) Inhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat). Breast Cancer Res Treat 137: 93–107. doi: 10.1007/s10549-012-2332-x
[16]
Mataga MA, Rosenthal S, Heerboth S, Devalapalli A, Kokolus S, et al. (2012) Anti-breast cancer effects of histone deacetylase inhibitors and calpain inhibitor. Anticancer Res 32: 2523–2529.
[17]
Papi A, Ferreri AM, Guerra F, Orlandi M (2012) Anti-invasive effects and proapoptotic activity induction by the rexinoid IIF and valproic acid in combination on colon cancer cell lines. Anticancer Res 32: 2855–2862.
[18]
Jin JS, Tsao TY, Sun PC, Yu CP, Tzao C (2012) SAHA inhibits the growth of colon tumors by decreasing histone deacetylase and the expression of cyclin D1 and survivin. Pathol Oncol Res 18: 713–720. doi: 10.1007/s12253-012-9499-7
[19]
Bergada L, Sorolla A, Yeramian A, Eritja N, Mirantes C, et al. (2013) Combination of Vorinostat and caspase-8 inhibition exhibits high anti-tumoral activity on endometrial cancer cells. Mol Oncol 7: 763–775. doi: 10.1016/j.molonc.2013.03.003
[20]
Singh BN, Zhou H, Li J, Tipton T, Wang B, et al. (2011) Preclinical studies on histone deacetylase inhibitors as therapeutic reagents for endometrial and ovarian cancers. Future Oncol 7: 1415–1428. doi: 10.2217/fon.11.124
[21]
Wang L, Xiang S, Williams KA, Dong H, Bai W, et al. (2012) Depletion of HDAC6 enhances cisplatin-induced DNA damage and apoptosis in non-small cell lung cancer cells. PLoS One 7: e44265. doi: 10.1371/journal.pone.0044265
[22]
Yang D, Torres CM, Bardhan K, Zimmerman M, McGaha TL, et al. (2012) Decitabine and vorinostat cooperate to sensitize colon carcinoma cells to Fas ligand-induced apoptosis in vitro and tumor suppression in vivo. J Immunol 188: 4441–4449. doi: 10.4049/jimmunol.1103035
[23]
Kim DH, Kim M, Kwon HJ (2003) Histone deacetylase in carcinogenesis and its inhibitors as anti-cancer agents. J Biochem Mol Biol 36: 110–119. doi: 10.5483/bmbrep.2003.36.1.110
[24]
Xu WS, Parmigiani RB, Marks PA (2007) Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26: 5541–5552. doi: 10.1038/sj.onc.1210620
[25]
Martinez-Iglesias O, Ruiz-Llorente L, Sanchez-Martinez R, Garcia L, Zambrano A, et al. (2008) Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer. Clin Transl Oncol 10: 395–398. doi: 10.1007/s12094-008-0221-x
[26]
Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769–784. doi: 10.1038/nrd2133
[27]
You BR, Park WH (2013) Trichostatin A induces apoptotic cell death of HeLa cells in a Bcl-2 and oxidative stress-dependent manner. Int J Oncol 42: 359–366. doi: 10.3892/ijo.2012.1705
[28]
You BR, Park WH (2010) Suberoyl bishydroxamic acid inhibits the growth of A549 lung cancer cells via caspase-dependent apoptosis. Mol Cell Biochem 344: 203–210. doi: 10.1007/s11010-010-0543-1
[29]
Miller CP, Ban K, Dujka ME, McConkey DJ, Munsell M, et al. (2007) NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood 110: 267–277. doi: 10.1182/blood-2006-03-013128
[30]
Yu C, Friday BB, Lai JP, McCollum A, Atadja P, et al. (2007) Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation. Clin Cancer Res 13: 1140–1148. doi: 10.1158/1078-0432.ccr-06-1751
[31]
Yaseen A, Chen S, Hock S, Rosato R, Dent P, et al. (2012) Resveratrol sensitizes acute myelogenous leukemia cells to histone deacetylase inhibitors through reactive oxygen species-mediated activation of the extrinsic apoptotic pathway. Mol Pharmacol 82: 1030–1041. doi: 10.1124/mol.112.079624
[32]
Petruccelli LA, Dupere-Richer D, Pettersson F, Retrouvey H, Skoulikas S, et al. (2011) Vorinostat induces reactive oxygen species and DNA damage in acute myeloid leukemia cells. PLoS One 6: e20987. doi: 10.1371/journal.pone.0020987
[33]
Robert C, Rassool FV (2012) HDAC inhibitors: roles of DNA damage and repair. Adv Cancer Res 116: 87–129. doi: 10.1016/b978-0-12-394387-3.00003-3
[34]
Llobet D, Eritja N, Encinas M, Sorolla A, Yeramian A, et al. (2008) Antioxidants block proteasome inhibitor function in endometrial carcinoma cells. Anticancer Drugs 19: 115–124. doi: 10.1097/cad.0b013e3282f24031
[35]
Sandoval J, Esteller M (2012) Cancer epigenomics: beyond genomics. Curr Opin Genet Dev 22: 50–55. doi: 10.1016/j.gde.2012.02.008
[36]
New M, Olzscha H, La Thangue NB (2012) HDAC inhibitor-based therapies: can we interpret the code? Mol Oncol 6: 637–656. doi: 10.1016/j.molonc.2012.09.003
[37]
Hu Y, Lu W, Chen G, Zhang H, Jia Y, et al. (2010) Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound beta-phenylethyl isothiocyanate. Blood 116: 2732–2741. doi: 10.1182/blood-2009-11-256354
[38]
Portanova P, Russo T, Pellerito O, Calvaruso G, Giuliano M, et al. (2008) The role of oxidative stress in apoptosis induced by the histone deacetylase inhibitor suberoylanilide hydroxamic acid in human colon adenocarcinoma HT-29 cells. Int J Oncol 33: 325–331. doi: 10.3892/ijo_00000012
[39]
Basu HS, Mahlum A, Mehraein-Ghomi F, Kegel SJ, Guo S, et al. (2011) Pretreatment with anti-oxidants sensitizes oxidatively stressed human cancer cells to growth inhibitory effect of suberoylanilide hydroxamic acid (SAHA). Cancer Chemother Pharmacol 67: 705–715. doi: 10.1007/s00280-010-1364-3
[40]
Nihal M, Roelke CT, Wood GS (2010) Anti-melanoma effects of vorinostat in combination with polyphenolic antioxidant (-)-epigallocatechin-3-gallate (EGCG). Pharm Res 27: 1103–1114. doi: 10.1007/s11095-010-0054-5
[41]
Fuchs-Tarlovsky V (2013) Role of antioxidants in cancer therapy. Nutrition 29: 15–21. doi: 10.1016/j.nut.2012.02.014
[42]
Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedelnikova OA, et al. (2008) GammaH2AX and cancer. Nat Rev Cancer 8: 957–967. doi: 10.1038/nrc2523
